Translational Pathways for Optical Drugs and Devices for Cancer Imaging
The Food and Drug Administration (FDA), in collaboration with the National Cancer Institute (NCI) and the University of Maryland Center for Excellence in Regulatory Science and Innovation (CERSI), is announcing a 1-day public workshop, “Translational Pathways for Optical Drugs and Devices for Cancer Imaging." The purpose of this workshop is to discuss regulatory expectations for the development of optical imaging drugs and devices and to identify efficient translational pathways forward to benefit patients. The workshop forum will hear the perspectives from industry, academia, investigators and other stakeholders on how to enhance the clinical development of optical imaging drugs and devices.
The public workshop will be held on:
Date: September 28, 2018
Time: 8:30 am to 4:30 pm (On-site check-in begins at 7:30 am)
The public workshop will be held at The Hotel at the University of Maryland, 7777 Baltimore Avenue, College Park, MD 20740. To book your stay, please contact the Hotel directly at (301) 277-7777 and request a room under the "Optical Imaging Workshop" room block.
Optical Imaging Workshop
To register for the public workshop, visit the following website: M-CERSI Events. Registrants will receive confirmation when they have been accepted. There is no registration fee to attend this public workshop in person, but there will be no on-site registration. Seats are limited and registration will be on a first-come, first-served basis
If you need special accommodations due to a disability, please contact Ann Anonsen at least 7 days in advance.
More Information: Contact Ann Anonsen, 301-405-0285; e-mail firstname.lastname@example.org